(Q36541961)

14 August 2017

1 reference

title

Infliximab for the treatment of psoriasis (English)

1 reference

14 August 2017

C Elise Kleyn

1

1 reference

14 August 2017

Christopher E M Griffiths

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

797-805

1 reference

Genome-wide studies of psoriasis susceptibility loci: a review

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

The challenges of treating moderate to severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Biological therapies in the systemic management of psoriasis: International Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

TNF-R1 signaling: a beautiful pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Biology of tumor necrosis factor-alpha- implications for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Signal transduction of inflammatory cytokines and tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

The role of cytokines in the immune response to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Tuberculosis and anti-TNF-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

21 January 2018

Infliximab for psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

Safety of tumour necrosis factor-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.8.797

21 January 2018

Identifiers

DOI

10.1517/14712598.6.8.797

1 reference

14 August 2017

1 reference